Literature DB >> 12757649

[Study on prenatal diagnosis using fluorescence quantitative polymerase chain reaction for congenital toxoplasmosis].

Yu-yan Ma1, Rui-li Mu, Lei-yi Wang, Sen Jiang.   

Abstract

OBJECTIVE: To investigate prenatal diagnosis and treatment of toxoplasmosis in fetuses with fluorescence quantitative polymerase chain reaction (FQ-PCR) technique.
METHODS: Of the 70 pregnant women with toxoplasma (TOX) DNA positive, TOX DNA in amniotic fluid and/or fetal umbilical cord blood was detected with FQ-PCR technique to diagnose fetal infection. 48 ones were given routine treatment with spiramycin for 2 therapy periods. Ultrasound examination were undertaken in all of pregnant women to monitor fetal growth.
RESULTS: Of the 70 cases with TOX DNA positive, TOX DNA was detected in 21 fetuses. TOX DNA positive rates were similar in amniotic fluid and umbilical cord blood. The higher the TOX DNA, the higher fetal infectious rate. Fetal infectious rate was lower in treatment group (21%) than that in control group (50%), there was a statistically difference between two groups.
CONCLUSIONS: Maternal TOX infection may cause fetal damage. Detection of TOX-DNA in amniotic fluid with FQ-PCR technique can diagnose fetal toxoplasmosis exactly. Treatment in pregnant period may decrease intrauterine infection rate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757649

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  2 in total

Review 1.  Polymerase chain reaction in the diagnosis of congenital toxoplasmosis: more than two decades of development and evaluation.

Authors:  Rashad Abdul-Ghani
Journal:  Parasitol Res       Date:  2011-01-11       Impact factor: 2.289

Review 2.  Performance of Polymerase Chain Reaction Analysis of the Amniotic Fluid of Pregnant Women for Diagnosis of Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis.

Authors:  Christianne Terra de Oliveira Azevedo; Pedro Emmanuel A A do Brasil; Letícia Guida; Maria Elizabeth Lopes Moreira
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.